Focused On-demand Library for Polycystin-2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q13563

UPID:
PKD2_HUMAN

ALTERNATIVE NAMES:
Autosomal dominant polycystic kidney disease type II protein; Polycystic kidney disease 2 protein; Polycystwin; R48321; Transient receptor potential cation channel subfamily P member 2

ALTERNATIVE UPACC:
Q13563; O60441; Q15764; Q2M1Q3; Q2M1Q5

BACKGROUND:
Polycystin-2, known for its roles in calcium signaling and mechanosensation, is crucial in maintaining the differentiated state of renal tubule cells. It forms both heteromeric and homotetrameric ion channels, facilitating the flow of K(+), Ca(2+), and Na(+) ions. This protein is essential in cilium length regulation and mechanotransductive signaling, playing a role in left-right axis specification and nodal flow detection in embryonic development.

THERAPEUTIC SIGNIFICANCE:
Given Polycystin-2's critical function in Polycystic kidney disease 2, targeting this protein offers a promising avenue for therapeutic intervention. The disease's link to Polycystin-2 underscores the importance of further research into how modulating this protein's activity could lead to innovative treatments for patients suffering from this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.